PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Yuyu Teijin Medicare Uses Drones to Deliver Medical Supplies to Patients on Korea's Remote Islands
SEOUL, South Korea , Sept. 29, 2026 /PRNewswire/ -- Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical ...
2026-09-29T    Health Care/Hospital   Infectious Disease Control   Medical Equipment   Medical/Pharmaceuticals 
Elsevier launches ClinicalKey Nursing AI, a new evidenced-based clinical AI solution built specifically for nurses
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care. ...
2026-09-29T    Health Care/Hospital   Higher Education   Medical Equipment   Medical/Pharmaceuticals 
Elsevier launches ClinicalKey Nursing AI, a new evidenced-based clinical AI solution built specifically for nurses
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care ...
2026-09-29T    Health Care/Hospital   Higher Education   Medical Equipment   Medical/Pharmaceuticals 
CAS announces collaboration with Novartis to advance AI-ready reaction informatics
Researchers will gain an integrated synthetic data foundation and an advanced custom search platform to support reaction data discovery and analysis   ...
2026-09-29T    Biotechnology   Computer/Electronics   Medical/Pharmaceuticals 
Providence Therapeutics Announces Formation of Oncology Clinical Advisory Board
CALGARY, AB , Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa
- Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
HRS-1596 is a phase I-ready GLP-1 /GIP dual receptor agonist for once-weekly oral dosing           Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Vitaceuticals Founders Win National Manufacturing Award for Australian-Made Health Range
Pharmacists Sally Tadros and Cyndi Khawaja recognised at the 2026 Australian Women's Small Business Champion Awards. ...
2026-09-29T    Health Care/Hospital   Medical/Pharmaceuticals 
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. ...
2026-09-29T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Regent Pacific (0575.HK)'s Deep Longevity Launches Accruaâ„¢ US Consumer Digital Health and Telehealth Platform
Available Across All 50 US States, Extending Deep Longevity's AI-Powered Ageing Science Directly to Consumers  for a Second Growth Curve ...
2026-09-28T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.